| 8.04 -0.14 (-1.71%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.66 |
1-year : | 10.13 |
| Resists | First : | 8.27 |
Second : | 8.68 |
| Pivot price | 8.15 |
|||
| Supports | First : | 7.61 |
Second : | 6.33 |
| MAs | MA(5) : | 8.21 |
MA(20) : | 8.18  |
| MA(100) : | 6.92 |
MA(250) : | 8.21 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 50.5 |
D(3) : | 55.7 |
| RSI | RSI(14): 50.1 |
|||
| 52-week | High : | 12.64 | Low : | 5.51 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ FOLD ] has closed above bottom band by 34.2%. Bollinger Bands are 19.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.15 - 8.2 | 8.2 - 8.23 |
| Low: | 7.86 - 7.91 | 7.91 - 7.96 |
| Close: | 7.96 - 8.04 | 8.04 - 8.11 |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Tue, 14 Oct 2025
Earnings call transcript: Amicus Therapeutics reports Q2 2025 earnings, stock dips - Investing.com
Fri, 10 Oct 2025
Equities Analysts Offer Predictions for FOLD Q4 Earnings - MarketBeat
Wed, 08 Oct 2025
Amicus Therapeutics (NASDAQ:FOLD) Given "Sell (E+)" Rating at Weiss Ratings - MarketBeat
Wed, 08 Oct 2025
Amicus Therapeutics (NASDAQ:FOLD) Upgraded to "Strong-Buy" at Zacks Research - MarketBeat
Wed, 08 Oct 2025
What Does Wall Street Think About Amicus Therapeutics (FOLD)? - Yahoo Finance
Tue, 07 Oct 2025
All You Need to Know About Amicus Therapeutics (FOLD) Rating Upgrade to Strong Buy - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 308 (M) |
| Shares Float | 288 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 104.2 (%) |
| Shares Short | 19,380 (K) |
| Shares Short P.Month | 22,180 (K) |
| EPS | -0.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.66 |
| Profit Margin | -6.7 % |
| Operating Margin | -5.1 % |
| Return on Assets (ttm) | 2 % |
| Return on Equity (ttm) | -22.7 % |
| Qtrly Rev. Growth | 22.1 % |
| Gross Profit (p.s.) | 1.67 |
| Sales Per Share | 1.85 |
| EBITDA (p.s.) | 0.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -46 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -67 |
| PEG Ratio | 0 |
| Price to Book value | 12.18 |
| Price to Sales | 4.33 |
| Price to Cash Flow | -54.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|